Another difficulty is the need for cell type specific therapies, as the α7 nAChR in lung cancer cells should be inhibited, while their activation in alveolar macrophages and epithelial cells could be useful in order for them to exert their anti-inflammatory properties. This evidence concerns the gene CHRNA7 and lung carcinoma.